ClinicalTrials.gg
RecruitingNCT07656454Updated Jun 30, 2026

A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants

A Phase 1 interventional study of CDR132L (i.v.) and CDR132L (s.c.) in Healthy Volunteers and Heart Failure, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Heart Failure by Novo Nordisk A/S — 5 open to participants now, 6 under way, 2 of them phase 3. Heart Failure · Novo Nordisk A/S.

Planned enrollment
8th of 11
32 · median 200
Started
2026
with 1 other
Phase 1
4 of 14
2 open now
Registered
14th of 14
by date

Among the 14 studies in Heart Failure by Novo Nordisk A/S, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 1, and was the 14th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 14 studies in Heart Failure by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is being done to understand how much of the medicine (CDR132L) enters the bloodstream after injection under the skin compared to injection into a vein in healthy people. This will help us find the best way to give the medicine to people living with heart failure. The study will assess what the body does to the medicine, and how safe it is.

03

Conditions studied

  • Healthy Volunteers
  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex at birth).
  • Age 18-55 years (both inclusive) at the time of signing the .
  • 18.5-29.9 kilograms per square metre (kg/m\^2) (both inclusive) and body weight less than or equal to (≤) 120 kilograms (kg) at screening (visit 1).
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit (visit 1), as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Any laboratory safety parameters at screening (visit 1) outside the below laboratory ranges, see laboratory manual for specific values.

    • (ALT) greater than (>) (ULN) +10 percentage (%)
    • Aspartate aminotransferase (AST) >ULN +20%
    • >ULN +20%
    • Creatinine >ULN +10%
    • Estimated (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) less than (\<) 90 milliliters per minute/1.73square meter (mL/min/1.73m\^2)
    • Urine albumin-to-creatinine ratio (UACR) greater than or equal to (≥) 30 milligrams per gram (mg/g)
  • Second or third degree atrioventricular-block, prolongation of the QRS complex over 120 milliseconds (ms), or of the corrected using Fridericia's formula (QTcF) interval over 450 ms, or any other abnormal results as judged by the investigator at screening (visit 1).
  • Supine blood pressure at screening (visit 1) outside the range of 90-139 millimeters of mercury (mmHg) for systolic or 50-89 mmHg for diastolic.
  • Heart rate outside the range of 50-89 beats/minute at screening (visit 1).
  • Presence or history (as declared by the participant or reported in the medical records) of cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischaemia, stroke, heart failure, cardiac decompensation, clinically significant arrhythmia and clinically significant conduction disorders.
  • Known history of severe symptomatic untreated anaemia in the 90 days prior to screening (visit 1) (e.g., \<90 grams per litre (g/L))
  • Presence or history (as declared by the participant or reported in the medical records) of acute or chronic kidney disease or injury.
  • Presence of thrombocytopenia, defined as count \<150 x 10\^9 cells/L at screening (visit 1), or history (as declared by the participant or reported in the medical records) of bleeding disorder.
  • Presence or history (as declared by the participant or reported in the medical records) of conditions associated with disruption of blood-brain barrier (e.g. multiple sclerosis).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Sequence A

    Participants will be given dose 1 of CDR132L intravenously, followed by dose 1 of CDR132L administered subcutaneously.

    Drug: CDR132L (i.v.) · Drug: CDR132L (s.c.)

  • Experimental
    Sequence B

    Participants will be given dose 1 of CDR132L subcutaneously, followed by dose 1 of CDR132L administered intravenously.

    Drug: CDR132L (i.v.) · Drug: CDR132L (s.c.)

  • Experimental
    Sequence C

    Participants will be given dose 2 of CDR132L intravenously, followed by dose 2 of CDR132L administered subcutaneously.

    Drug: CDR132L (i.v.) · Drug: CDR132L (s.c.)

  • Experimental
    Sequence D

    Participants will be given dose 2 of CDR132L subcutaneously, followed by dose 2 of CDR132L administered intravenously.

    Drug: CDR132L (i.v.) · Drug: CDR132L (s.c.)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the CDR132L plasma concentration-time curve (AUC 0-tz) from 0 hours to tz after a single dose, where tz is the time of last quantifiable concentration

    Measured as hours\*nanograms per milliliter (h\*ng/mL)

    Time frame: From 0 to 840 hours after CDR132L administration

Secondary outcomes

  1. Area under the CDR132L plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose

    Measured as h\*ng/mL

    Time frame: From 0 to 840 hours after CDR132L administration

  2. Maximum observed CDR132L plasma concentration after a single dose

    Measured as nanograms per milliliter (ng/mL)

    Time frame: From 0 to 840 hours after CDR132L administration

  3. Time to maximum observed CDR132L plasma concentration after a single dose

    Measured in hours

    Time frame: From 0 to 840 hours after CDR132L administration

  4. Terminal half-life for CDR132L after a single dose

    Measured in hours

    Time frame: From 0 to 840 hours after CDR132L administration

  5. Area under the CDR132L plasma concentration-time curve from 0 hours to tz after a single dose, where tz is the time of last quantifiable concentration, divided by dose

    Measured as hours\*nanograms per milliliter per milligram (h\*ng/mL/mg)

    Time frame: From 0 to 840 hours after CDR132L administration

  6. Maximum observed CDR132L plasma concentration after a single dose divided by dose

    Measured as nanograms per milliliter per milligram (ng/mL/mg)

    Time frame: From 0 to 840 hours after CDR132L administration

  7. Total plasma clearance of CDR132L after a single dose

    Measured as liters per hour

    Time frame: From 0 to 840 hours after CDR132L administration

  8. Apparent volume of distribution of CDR132L after a single dose based on plasma concentration values

    Measured in liters

    Time frame: From 0 to 840 hours after CDR132L administration

  9. Mean residence time for CDR132L after a single dose

    Measured in hours

    Time frame: From 0 to 840 hours after CDR132L administration

  10. Number of adverse events

    Measured as number of events

    Time frame: From first CDR132L administration (day 1) to day 141

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's planned 6 months is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2026
First posted
Jun 18, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07656454
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Jun 17, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 30, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDR132L

Start the discussion